Mango Medical Wants Every Orthopedic Surgery to Follow a Personalized AI Plan

The Macro: Surgical Planning Is Still Painfully Manual

Orthopedic surgery is one of the highest-volume surgical specialties in the world. Hip replacements, knee replacements, spinal fusions, fracture repairs. Millions of procedures per year, each requiring a detailed surgical plan based on patient-specific anatomy.

The current surgical planning process is slow. A surgeon or planning technician takes CT scan data, loads it into planning software, manually segments the anatomy, measures angles and distances, selects implant sizes, and creates a step-by-step operative plan. This can take hours to days per case, depending on complexity. For high-volume surgeons doing 5 to 10 cases per week, the planning burden is significant.

The existing planning tools from companies like Materialise, Stryker’s Blueprint, and Zimmer Biomet’s Signature are helpful but still require substantial manual input. They are essentially advanced measurement tools, not autonomous planning systems. The surgeon still makes most of the decisions about approach, implant selection, and technique.

Mango Medical, backed by Y Combinator, is building agentic surgical planning AI that takes a CT scan and delivers a surgeon-ready plan in minutes. Not a draft. Not a suggestion. A complete, actionable surgical plan.

The Micro: From Scan to Plan in Minutes

Adrian Kilian (CEO) brings an unusual background. He is a dentist and maxillofacial surgery researcher, Stanford GSB Ignite alumni, and former voice actor. Jorge Padilla Perez (CTO) contributed to the original U-NET paper, which is foundational to medical image segmentation, and has collaborated with ETH Zurich, Stanford, and TU Munich on medical imaging research.

The CTO’s involvement with U-NET is significant. U-NET is the architecture that enabled accurate medical image segmentation and is used in virtually every modern medical imaging AI product. Having someone who helped create that foundation building the product gives Mango Medical deep technical credibility.

The company claims an 8-figure letter of intent from a top orthopedic company, which is a strong commercial signal for a company at this stage. They are also pursuing FDA 510(k) clearance, the standard regulatory pathway for surgical planning software that is substantially equivalent to existing cleared devices.

The technical challenge is moving from segmentation (identifying anatomical structures in a CT scan) to planning (making clinical decisions about implant type, size, positioning, and surgical approach). This requires not just computer vision but clinical reasoning. The “agentic” framing suggests the AI is making planning decisions autonomously rather than just providing measurements.

Competitors include Materialise (3D printing and surgical guides), Stryker’s Mako system (robotic surgery with integrated planning), and newer entrants like Enhatch. The difference is speed: if Mango can deliver a quality plan in minutes instead of hours, high-volume surgical practices save enormous amounts of technician and surgeon time.

The Verdict

Mango Medical is attacking a large, validated market with strong technical foundations. The surgical planning market is proven, the regulatory pathway is clear, and the founding team has the right backgrounds.

At 30 days: is the 8-figure LOI converting to a signed contract? LOIs are encouraging but non-binding.

At 60 days: what is the FDA 510(k) submission timeline looking like? Regulatory clearance is the gate that determines when this product can be sold commercially.

At 90 days: how do surgeons rate the AI-generated plans compared to manually created ones? Surgeon trust is the ultimate bottleneck for adoption.

I am optimistic about Mango Medical. The technical team is strong, the commercial traction is early but meaningful, and the problem is real. If they can get FDA clearance and deliver plans that surgeons actually trust, this becomes a standard tool in every orthopedic practice.